A Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

A Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 May 2017

At a glance

  • Drugs TD 139 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Galecto Biotech
  • Most Recent Events

    • 24 May 2017 Results (n=24) of part II, presented at the 113th International Conference of the American Thoracic Society
    • 10 Mar 2017 Results published in a Galecto Biotech media release.
    • 10 Mar 2017 Detailed results from this trial will be presented at the meeting of the American Thoracic Society, according to a Galecto Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top